Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

LVADs as destination therapy

Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.

Key clinical point: Landmark trial paves way to much wider use of LVADs as destination therapy.

Major finding: The 2-year rate of survival free of disabling stroke or reoperation to replace or remove a malfunctioning LVAD was 79.5% with the novel HeartMate 3 LVAD, compared with 60.2% with the commonly used HeartMate II axial-flow device.

Study details: This was a randomized, unblinded, multicenter study of more than 1,000 patients with advanced heart failure.

Disclosures: The MOMENTUM 3 trial was funded by Abbott. The presenter reported receiving research grants from and serving as a consultant to the company.

Source: Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.

Read the article.

Citation:

Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.